MA5-13512

antibody from Invitrogen Antibodies

Targeting: TYMS HsT422, TMS, TS, Tsase

Provider product page for MA5-13512

Western blot

Other assay

Antibody data

Antibody Data
Antigen structure
References [33]
Comments [0]
Validations
Western blot [1]
Other assay [1]

Submit

Product number: MA5-13512 - Provider product page
Provider: Invitrogen Antibodies
Product name: Thymidylate Synthase Monoclonal Antibody (TS 106)
Antibody type: Monoclonal
Antigen: Recombinant full-length protein
Description: MA5-13512 targets Thymidylate Synthase in ELISA, FACS, IF, IP, and WB applications and shows reactivity with Human samples.
Antibody clone number: TS 106
Concentration: 0.2 mg/mL

TYMS protein structure - MA5-13512 shown in red.

Submitted references Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.

Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R, CLICaP
PloS one 2016;11(5):e0154293

Impact of intratumoral expression levels of fluoropyrimidine-metabolizing enzymes on treatment outcomes of adjuvant S-1 therapy in gastric cancer.

Kim JY, Shin E, Kim JW, Lee HS, Lee DW, Kim SH, Lee JO, Kim YJ, Kim JH, Bang SM, Ahn SH, Park DJ, Lee JS, Lee JS, Kim HH, Lee KW
PloS one 2015;10(3):e0120324

Molecular profiling in gastric cancer: examining potential targets for chemotherapy.

Miura JT, Johnston FM, Thomas J, George B, Eastwood D, Tsai S, Christians KK, Turaga KK, Gamblin TC
Journal of surgical oncology 2014 Sep;110(3):302-6

Thymidylate synthase, topoisomerase-1 and microsatellite instability: relationship with outcome in mucinous colorectal cancer treated with fluorouracil.

Negri FV, Azzoni C, Bottarelli L, Campanini N, Mandolesi A, Wotherspoon A, Cunningham D, Scartozzi M, Cascinu S, Tinelli C, Silini EM, Ardizzoni A
Anticancer research 2013 Oct;33(10):4611-7

Excision repair cross complementation group 1 and thymidylate synthase expression in patients with mesothelioma.

Kao SC, Lee K, Klebe S, Henderson D, McCaughan B, Vardy J, Clarke S, van Zandwijk N
Clinical lung cancer 2013 Mar;14(2):164-71

Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.

Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2013 Apr;8(4):469-77

Translational repression of thymidylate synthase by targeting its mRNA.

Garg D, Beribisky AV, Ponterini G, Ligabue A, Marverti G, Martello A, Costi MP, Sattler M, Wade RC
Nucleic acids research 2013 Apr;41(7):4159-70

Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell lines.

Giudice S, Benassi L, Bertazzoni G, Veratti E, Morini D, Azzoni P, Costi MP, Venturelli A, Pirondi S, Seidenari S, Magnoni C
Investigational new drugs 2012 Aug;30(4):1484-92

Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer.

Lee SJ, Choi YL, Park YH, Kim ST, Cho EY, Ahn JS, Im YH
Cancer chemotherapy and pharmacology 2011 Sep;68(3):743-51

Bax predicts outcome in gastric cancer patients treated with 5-fluorouracil, leucovorin, and oxaliplatin palliative chemotherapy.

Jeong SH, Han JH, Kim JH, Ahn MS, Hwang YH, Lee HW, Kang SY, Park JS, Choi JH, Lee KJ, Sheen SS, Lim HY
Digestive diseases and sciences 2011 Jan;56(1):131-8

Thymidine synthase, thymidine phosphorylase, and excision repair cross-complementation group 1 expression as predictive markers of capecitabine plus cisplatin chemotherapy as first-line treatment for patients with advanced oesophageal squamous cell carcinoma.

Lee S, Park YH, Kim KH, Cho EY, Ahn YC, Kim K, Shim YM, Ahn JS, Park K, Im YH
British journal of cancer 2010 Sep 7;103(6):845-51

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

Righi L, Papotti MG, Ceppi P, Billè A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010 Mar 20;28(9):1534-9

Topoisomerase I but not thymidylate synthase is associated with improved outcome in patients with resected colorectal cancer treated with irinotecan containing adjuvant chemotherapy.

Kostopoulos I, Karavasilis V, Karina M, Bobos M, Xiros N, Pentheroudakis G, Kafiri G, Papakostas P, Vrettou E, Fountzilas G
BMC cancer 2009 Sep 24;9:339

Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer.

Han SW, Oh DY, Im SA, Park SR, Lee KW, Song HS, Lee NS, Lee KH, Choi IS, Lee MH, Kim MA, Kim WH, Bang YJ, Kim TY
British journal of cancer 2009 Jan 27;100(2):298-304

Thymidylate synthase and microsatellite instability in colorectal cancer: implications for disease free survival, treatment response and survival with metastases.

Bendardaf R, Lamlum H, Ristamäki R, Korkeila E, Syrjänen K, Pyrhönen S
Acta oncologica (Stockholm, Sweden) 2008;47(6):1046-53

Modified FOLFOX-6 chemotherapy in advanced gastric cancer: Results of phase II study and comprehensive analysis of polymorphisms as a predictive and prognostic marker.

Keam B, Im SA, Han SW, Ham HS, Kim MA, Oh DY, Lee SH, Kim JH, Kim DW, Kim TY, Heo DS, Kim WH, Bang YJ
BMC cancer 2008 May 27;8:148

Adjuvant chemotherapy in completely resected gastric cancer: a randomized phase III trial conducted by GOIRC.

Di Costanzo F, Gasperoni S, Manzione L, Bisagni G, Labianca R, Bravi S, Cortesi E, Carlini P, Bracci R, Tomao S, Messerini L, Arcangeli A, Torri V, Bilancia D, Floriani I, Tonato M, Italian Oncology Group for Cancer Research, Dinota A, Strafiuso G, Corgna E, Porrozzi S, Boni C, Rondini E, Giunta A, Monzio Compagnoni B, Biagioni F, Cesari M, Fornarini G, Nelli F, Carboni M, Cognetti F, Enzo MR, Piga A, Romiti A, Olivetti A, Masoni L, De Stefanis M, Dalla Mola A, Camera S, Recchia F, De Filippis S, Scipioni L, Zironi S, Luppi G, Italia M, Banducci S, Pisani Leretti A, Massidda B, Ionta MT, Nicolosi A, Canaletti R, Biscottini B, Grigniani F, Di Costanzo F, Rovei R, Croce E, Carroccio R, Gilli G, Cavalli C, Olgiati A, Pandolfi U, Rossetti R, Natalini G, Foa P, Oldani S, Bruno L, Cascinu S, Catalano G, Catalano V, Lungarotti F, Farris A, Sarobba MG, Trignano M, Muscogiuri A, Francavilla F, Figoli F, Leoni M, Papiani G, Orselli G, Antimi M, Bellini V, Cabassi A, Contu A, Pazzola A, Frignano M, Lastraioli E, Saggese M, Bianchini D, Antonuzzo L, Mela M, Camisa R
Journal of the National Cancer Institute 2008 Mar 19;100(6):388-98

Thymidylate synthase in situ protein expression and survival in stage I nonsmall-cell lung cancer.

Zheng Z, Li X, Schell MJ, Chen T, Boulware D, Robinson L, Sommers E, Bepler G
Cancer 2008 Jun 15;112(12):2765-73

ERCC1 predicting chemoradiation resistance and poor outcome in oesophageal cancer.

Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Kim SB
European journal of cancer (Oxford, England : 1990) 2008 Jan;44(1):54-60

Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.

Correale P, Del Vecchio MT, La Placa M, Montagnani F, Di Genova G, Savellini GG, Terrosi C, Mannucci S, Giorgi G, Francini G, Cusi MG
Journal of immunotherapy (Hagerstown, Md. : 1997) 2008 Feb-Mar;31(2):132-47

Pemetrexed, a multitargeted antifolate drug, demonstrates lower efficacy in comparison to methotrexate against osteosarcoma cell lines.

Bodmer N, Walters DK, Fuchs B
Pediatric blood & cancer 2008 Apr;50(4):905-8

Increased expression of thymidylate synthetase (TS), ubiquitin specific protease 10 (USP10) and survivin is associated with poor survival in glioblastoma multiforme (GBM).

Grunda JM, Nabors LB, Palmer CA, Chhieng DC, Steg A, Mikkelsen T, Diasio RB, Zhang K, Allison D, Grizzle WE, Wang W, Gillespie GY, Johnson MR
Journal of neuro-oncology 2006 Dec;80(3):261-74

5-fluorouracil-based chemotherapy enhances the antitumor activity of a thymidylate synthase-directed polyepitopic peptide vaccine.

Correale P, Del Vecchio MT, Di Genova G, Savellini GG, La Placa M, Terrosi C, Vestri M, Urso R, Lemonnier F, Aquino A, Bonmassar E, Giorgi G, Francini G, Cusi MG
Journal of the National Cancer Institute 2005 Oct 5;97(19):1437-45

High thymidylate synthase expression in colorectal cancer with microsatellite instability: implications for chemotherapeutic strategies.

Ricciardiello L, Ceccarelli C, Angiolini G, Pariali M, Chieco P, Paterini P, Biasco G, Martinelli GN, Roda E, Bazzoli F
Clinical cancer research : an official journal of the American Association for Cancer Research 2005 Jun 1;11(11):4234-40

Humoral immune response to thymidylate synthase in colon cancer patients after 5-FU chemotherapy.

Shebzukhov YV, Koroleva EP, Khlgatian SV, Lagarkova MA, Meshcheryakov AA, Lichinitser MR, Karbach J, Jager E, Kuprash DV, Nedospasov SA
Immunology letters 2005 Aug 15;100(1):88-93

Role of biological markers in the clinical outcome of colon cancer.

Nanni O, Volpi A, Frassineti GL, De Paola F, Granato AM, Dubini A, Zoli W, Scarpi E, Turci D, Oliverio G, Gambi A, Amadori D
British journal of cancer 2002 Oct 7;87(8):868-75

Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts.

Gribaudo G, Riera L, Rudge TL, Caposio P, Johnson LF, Landolfo S
The Journal of general virology 2002 Dec;83(Pt 12):2983-93

Human cytomegalovirus infection induces cellular thymidylate synthase gene expression in quiescent fibroblasts.

Gribaudo G, Riera L, Rudge TL, Caposio P, Johnson LF, Landolfo S
The Journal of general virology 2002 Dec;83(Pt 12):2983-93

Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Jin J, Huang M, Wei HL, Liu GT
World journal of gastroenterology 2002 Dec;8(6):1029-34

Mechanism of 5-fluorouracil required resistance in human hepatocellular carcinoma cell line Bel(7402).

Jin J, Huang M, Wei HL, Liu GT
World journal of gastroenterology 2002 Dec;8(6):1029-34

The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase.

Gribaudo G, Riera L, Lembo D, De Andrea M, Johnson LF, Landolfo S
Virus research 2001 Jan;73(1):57-65

The anticytomegaloviral activity of raltitrexed is abrogated in quiescent mouse fibroblasts that overexpress thymidylate synthase.

Gribaudo G, Riera L, Lembo D, De Andrea M, Johnson LF, Landolfo S
Virus research 2001 Jan;73(1):57-65

Murine cytomegalovirus stimulates cellular thymidylate synthase gene expression in quiescent cells and requires the enzyme for replication.

Gribaudo G, Riera L, Lembo D, De Andrea M, Gariglio M, Rudge TL, Johnson LF, Landolfo S
Journal of virology 2000 Jun;74(11):4979-87

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Western blot of Thymidylate Synthase using Thymidylate Synthase Monoclonal Antibody (Product # MA5-13512) on TS Cells.

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Immunoprecipitation of Thymidylate Synthase using Thymidylate Synthase Monoclonal Antibody (Product # MA5-13512) on Native Human TS Cells.